Patrick Burnett

Patrick Burnett

Company: Arcutis

Job title: Senior Vice President & Chief Medical Officer


Delivering on the Non-steroidal Promise, Roflumilast: A Potent Topical PDE-4 inhibitor in Development for the Treatment of Psoriasis, Atopic Dermatitis & Seborrheic Dermatitis 2:00 pm

• Examining completed Phase 3 studies in psoriasis with roflumilast cream which demonstrates favorable safety and efficacy with treatment up to 52 weeks • Exploring Phase 3 studies in Atopic Dermatitis with roflumilast cream ongoing in subjects ages 2 and above • Discussing successful Phase 2 studies with a foam formulation in subjects with seborrheic…Read more

day: Day 1 PM - Track 2

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.